KERX Financial Facts

License revenue: 256K
Total operating expenses: 35.65M
See Full Income Statement

Total liabilities: 28.2M
Property, plant and equipment, net: 1.36M
See Full Balance Sheet

Keryx Biopharmaceuticals Inc. (KERX) Earnings

  |   Expand Research on KERX
Next EPS Date 5/8/15 *Est. EPS Growth Rate -109.5% *Last Qtr.
Average EPS % Beat Rate -35.8% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +2.5% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/6/14 Q314 -$0.38-$0.27 -$0.11$256K$150K N/A Details
11/4/13 Q313 -$0.19-$0.11 -$0.08N/A$2.22M N/A Details
5/8/14 Q114 -$0.15-$0.08 -$0.07$10M$9.91M N/A Details
2/27/15 Q414 -$0.44-$0.37 -$0.07$569K$1.39M N/A Details
3/12/14 Q413 -$0.21-$0.16 -$0.05N/A$2.22M N/A Details
7/31/13 Q213 -$0.14-$0.10 -$0.04N/AN/A N/A Details
11/2/11 Q311 -$0.15-$0.12 -$0.03N/AN/A N/A Details
3/8/11 Q410 -$0.09-$0.06 -$0.03N/A$2.82M N/A Details